16:48 EDT Protagonist Therapeutics (PTGX) files automatic mixed securities shelf
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTGX:
- Protagonist Therapeutics reports Q2 EPS (55c), consensus (52c)
- Protagonist Therapeutics’ Rusfertide Study: Long-term Safety in Focus
- Optimistic Buy Rating for Protagonist Therapeutics Driven by Promising NDA Submission and Market Potential of Icotrokinra
- Protagonist Therapeutics Positioned for Growth with Icotrokinra’s Strong FDA Approval Prospects and Strategic Partnerships
- Protagonist Therapeutics, Johnson & Johnson submit icotrokinra NDA to FDA